10-Q: Cibus Inc. Reports Second Quarter 2024 Results, Highlights Progress in Trait Development and Commercialization

Cibus Inc. announced its second quarter 2024 results, showcasing advancements in its trait development pipeline and commercialization efforts, alongside ongoing financial challenges.

Summary

• Cibus Inc. reported a net loss of $28.5 million for the second quarter of 2024, compared to a net loss of $20.5 million for the same period in 2023.
• The company's revenue increased to $0.8 million in Q2 2024, up from $0.2 million in Q2 2023, driven by collaboration agreements.
• Research and development expenses rose to $13.0 million in Q2 2024, compared to $8.4 million in Q2 2023, due to the merger with Cibus Global.
• Selling, general, and administrative expenses decreased to $9.3 million in Q2 2024, down from $11.1 million in Q2 2023, due to one-time merger expenses in the prior year.
• The company's royalty liability interest expense was $8.7 million in Q2 2024, compared to $2.6 million in Q2 2023, due to the assumption of the liability in the merger.
• Cibus reported a net loss of $55.5 million for the first six months of 2024, with cash used in operating activities of $30.5 million.
• As of June 30, 2024, Cibus had $30.0 million in cash and cash equivalents and $29.0 million in current liabilities.
• The company issued 927,326 shares of Class A Common Stock through its ATM facility, generating net proceeds of $16.5 million during the first six months of 2024.
• Cibus also completed a registered direct offering in June 2024, issuing 1,298,040 shares of Class A Common Stock and warrants, generating net proceeds of $12.0 million.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive developments in trait development and regulatory approvals, the company's financial situation is concerning, with increasing losses and a need for additional capital. This creates a cautious outlook.

Positives

• Revenue increased significantly due to collaboration agreements.
• The company made significant progress in its herbicide platform for rice, securing agreements with major seed companies.
• Cibus achieved key milestones in its advanced trait development, including successful edits for Sclerotinia resistance in Canola.
• The addition of a Nutrient Use Efficiency trait demonstrates the company's ability to integrate third-party technologies.
• Cibus secured additional funding for its sustainable ingredients program.
• The company's intellectual property portfolio was strengthened with new patents.
• Regulatory environments are becoming more favorable for gene editing technologies.

Negatives

• The company experienced a net loss of $28.5 million in Q2 2024, an increase from $20.5 million in Q2 2023.
• Research and development expenses increased significantly due to the merger with Cibus Global.
• The company's royalty liability interest expense increased substantially due to the merger.
• Cibus has an accumulated deficit of $528.1 million and expects to continue incurring losses.
• The company's cash and cash equivalents are not sufficient to fund operations for the next 12 months.

Risks

• The company's ability to continue as a going concern is dependent on raising additional capital.
• There is a risk that the company may need to implement more stringent cost reduction measures or scale back operations if additional capital is not secured.
• The company faces challenges in commercializing its traits and generating sufficient revenue.
• The company's financial performance is subject to fluctuations in the market and macroeconomic conditions.
• There is a risk of dilution to existing stockholders if additional equity is raised.
• The company is dependent on distributions from Cibus Global to cover its corporate expenses.
• Regulatory developments could disfavor or impose burdens on gene editing processes or products.

Future Outlook

The company expects to continue to incur significant expenses and operating losses for the next several years. Cibus anticipates that it will continue to generate losses for the next several years. Over the longer term and until the Company can generate cash flows sufficient to support its operating capital requirements, it expects to finance a portion of future cash needs through (i) cash on hand, (ii) commercialization activities, which may result in various types of revenue streams from future product development agreements and technology licenses, including upfront and milestone payments, annual license fees, and royalties, (iii) government or other third party funding, (iv) public or private equity or debt financings, or (v) a combination of the foregoing.

Management Comments

• Cibus believes that its RTDS technologies and Trait Machine process represent a technological breakthrough in plant breeding.
• Cibus believes that its gene editing technologies and trait products have the potential to accelerate agricultures jump to a climate smart, more sustainable, crop production system.
• Cibus believes the impact of these regulations is the beginning of the gene editing era.

Industry Context

The report highlights the evolving regulatory landscape for gene editing technologies, with Canada and the EU moving towards treating gene-edited traits similarly to those developed through conventional breeding. This shift is significant for Cibus, as it aligns with the company's technology and business model, potentially opening up new markets and reducing regulatory hurdles.

Comparison to Industry Standards

• Cibus' focus on high-throughput gene editing facilities aligns with the industry's move towards more efficient and scalable breeding processes, similar to companies like Pairwise and Benson Hill.
• The company's development of multiple traits across different crops, including Canola, Rice, and Soybean, is comparable to other agricultural biotech companies with diverse product pipelines.
• Cibus' emphasis on traits that address productivity and sustainability challenges, such as disease resistance and nutrient use efficiency, is consistent with the industry's focus on developing climate-smart agricultural solutions.
• The company's commercialization strategy, which involves licensing traits to seed companies, is a common approach in the agricultural biotech sector, similar to companies like Corteva and Bayer.
• The company's financial results, including its net losses and cash burn, are typical for early-stage biotech companies that are investing heavily in research and development.

Related Party Transactions

• Cellectis, the Company's largest shareholder prior to the completion of the Merger Transactions, has guaranteed the lease agreement for the Companys Roseville, Minnesota facility.

Stakeholder Impact

• Shareholders face the risk of dilution and potential loss of investment if the company is unable to secure additional funding.
• Employees may be impacted by potential cost reduction measures or scaling back of operations.
• Customers, primarily seed companies, will benefit from the company's trait development and commercialization efforts.
• Suppliers may be impacted by potential changes in the company's operations and spending.
• Creditors face the risk of non-payment if the company is unable to secure additional funding.

Next Steps

• The company will continue to advance its trait development pipeline.
• Cibus will focus on commercializing its traits through partnerships with seed companies.
• The company will continue to seek additional funding to support its operations.
• Cibus will continue to monitor and adapt to the evolving regulatory landscape for gene editing technologies.
• The company will continue to develop its Soybean platform.

Key Dates

Keywords

gene editing, plant traits, agriculture, biotechnology, crop productivity, trait development, RTDS, herbicide tolerance, sclerotinia resistance, nutrient use efficiency, sustainable ingredients, commercialization, seed companies